Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYNK-001 for the Treatment of Adults With COVID-19
NCT04365101Phase 2Terminated
- Sponsor
- Celularity Inc.
- Start
- Sep 2020
- Primary completion
- Aug 2021
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of CYNK-001 in coronavirus disease 2019 (COVID-19) (2 arms), sponsored by Celularity Inc. Primary endpoint: Frequency and Severity of Adverse Events at 6 months. Started Sep 2020; status: terminated.
02
Drugs
CYNK-001
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04365101.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04365101.